Avalo Therapeutics (AVTX) Total Liabilities (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Total Liabilities came in at $31.6 million in Q1 2026, up 98.42% YoY from $15.9 million in Q1 2025, and down 5.52% on a QoQ basis from $33.4 million in Q4 2025.
Avalo Therapeutics (AVTX) Total Liabilities (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Total Liabilities data on file, last reported at $31.6 million in Q1 2026.
- Quarterly Total Liabilities rose 98.42% year-over-year to $31.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.6 million (up 98.42% YoY) and the FY2025 annual result came in at $33.4 million, up 88.75% from the prior year.
- Total Liabilities slipped to $31.6 million in Q1 2026, from $33.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $224.8 million in Q1 2024 to a low of $13.7 million in Q4 2023.
- A 5-year average of $49.6 million and a median of $33.6 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 428.95% — and 2025, when it slumped 92.92%.
- Tracing AVTX's Total Liabilities over 5 years: stood at $44.3 million in 2022, then sank by 69.09% to $13.7 million in 2023, then grew by 29.3% to $17.7 million in 2024, then soared by 88.75% to $33.4 million in 2025, then decreased by 5.52% to $31.6 million in 2026.
- The last three Total Liabilities figures came in at $31.6 million (Q1 2026), $33.4 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 42.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.12 Mn |
| Mar 31, 2026 | 31.57 Mn |
| Dec 31, 2025 | 33.41 Mn |
| Sep 30, 2025 | 33.55 Mn |
| Jun 30, 2025 | 22.01 Mn |
| Mar 31, 2025 | 15.91 Mn |
| Dec 31, 2024 | 17.70 Mn |
| Sep 30, 2024 | 75.72 Mn |
| Jun 30, 2024 | 110.46 Mn |
| Mar 31, 2024 | 224.81 Mn |
| Dec 31, 2023 | 13.69 Mn |
| Sep 30, 2023 | 14.58 Mn |
| Jun 30, 2023 | 31.20 Mn |
| Mar 31, 2023 | 42.50 Mn |
| Dec 31, 2022 | 44.28 Mn |
| Sep 30, 2022 | 38.58 Mn |
| Jun 30, 2022 | 38.18 Mn |
| Mar 31, 2022 | 55.56 Mn |
| Dec 31, 2021 | 57.13 Mn |
| Sep 30, 2021 | 55.05 Mn |